Sigilon Therapeutics to Present at Cowen & Company 38th Annual Health Care Conference

News Releases  |  March 14th, 2018

CAMBRIDGE, Mass., March 9, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conference. Presentation details are as follows:

Cowen & Company 38th Annual Health Care Conference

Presenter:                          Paul Wotton, Ph.D., Chief Executive Officer

Date:                                   Monday, March 12, 2018

Time:                                   10 a.m. EDT

Location:                            Boston Marriott Copley Place

About Sigilon Therapeutics

 Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.

Sigilon Contact
Lori Kelley
(617) 336-7541
lori@sigilon.com

 Media Contacts
Rich Allan or David Schull
Russo Partners, LLC
(646) 942-5588
(212) 845-4271
rich.allan@russopartnersllc.com
david.schull@russopartnersllc.com


Read More